bendamustine + rituximab + ibrutinib (Institute of Hematology and Blood Diseases Hospital)

bendamustine + rituximab + ibrutinib is a combination chemoimmunotherapy and targeted therapy regimen being investigated for the treatment of chronic lymphocytic leukemia (CLL). The regimen combines bendamustine, a nitrogen mustard alkylating agent that causes DNA cross-linking; rituximab, a chimeric monoclonal antibody targeting the CD20 antigen on B-cells; and ibrutinib, an oral small molecule that covalently inhibits Bruton tyrosine kinase (BTK). This specific protocol, studied by the Institute of Hematology & Blood Diseases Hospital in China, explores an alternating schedule of the BR (bendamustine and rituximab) backbone with ibrutinib. The goal of this approach is to achieve deep molecular responses and potentially allow for fixed-duration therapy in treatment-naive CLL patients, balancing the efficacy of traditional chemotherapy with the precision of BTK inhibition.

Other names

BR and ibrutinibBR + ibrutinibBR alternating with ibrutinib